Business Context and Reporting Period
This Form 8-K Current Report was filed by IDEAYA Biosciences, Inc. on April 2, 2025, regarding events occurring on March 28, 2025. The filing addresses corporate governance changes specifically related to the Board of Directors ahead of the 2025 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters and contains no financial performance data.
Material Changes
- Board Departure: Susan L. Kelley, M.D., has notified the Company of her decision not to stand for re-election to the Board of Directors.
- Resignation Timing: Dr. Kelley will resign immediately after the conclusion of the 2025 Annual Meeting of Stockholders.
- Board Size Reduction: The Company anticipates decreasing the Board size to seven (7) directors effective upon the conclusion of the Annual Meeting.
- Reason for Departure: The filing explicitly states the decision is not the result of any disagreement with the Company regarding operations, policies, or practices.
Outlook and Management Commentary
- Advisory Role: Dr. Kelley intends to transition into an advisory role as Chair of the Company's new Clinical Advisory Board.
- New Committee: The Clinical Advisory Board is expected to be established prior to the Annual Meeting.
- Risks and Contingencies: No specific risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Confirm the exact date of the 2025 Annual Meeting of Stockholders to determine the precise effective date of the Board size reduction.
- Verify the formal establishment and charter of the new Clinical Advisory Board.
- Monitor subsequent filings for the election of any new directors to fill the vacancy left by Dr. Kelley, if applicable.
- Review the Company's proxy statement for the 2025 Annual Meeting for further details on the Board composition and director nominations.